Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fit-for-Purpose Ki-67 Immunohistochemistry Assays for Breast Cancer.
Torlakovic EE, Baniak N, Barnes PJ, Chancey K, Chen L, Cheung C, Clairefond S, Cutz JC, Faragalla H, Gravel DH, Dakin Hache K, Iyengar P, Komel M, Kos Z, Lacroix-Triki M, Marolt M, Mrkonjic M, Mulligan AM, Nofech-Mozes S, Park PC, Plotkin A, Raphael S, Rees H, Seno HR, Thai DV, Troxell ML, Varma S, Wang G, Wang T, Wehrli B, Bigras G. Torlakovic EE, et al. Among authors: lacroix triki m. Lab Invest. 2024 May 8:102076. doi: 10.1016/j.labinv.2024.102076. Online ahead of print. Lab Invest. 2024. PMID: 38729353 Free article.
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial.
Giacchetti S, Laas E, Bachelot T, Lemonnier J, André F, Cameron D, Bliss J, Chabaud S, Hardy-Bessard AC, Lacroix-Triki M, Canon JL, Debled M, Campone M, Cottu P, Dalenc F, Ballesta A, Penault-Llorca F, Asselain B, Dumas E, Reyal F, Gougis P, Lévi F, Hamy AS. Giacchetti S, et al. Among authors: lacroix triki m. EBioMedicine. 2024 May 7;104:105141. doi: 10.1016/j.ebiom.2024.105141. Online ahead of print. EBioMedicine. 2024. PMID: 38718683 Free PMC article.
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T. Penault-Llorca F, et al. Among authors: lacroix triki m. ESMO Open. 2024 Apr 30;9(5):103443. doi: 10.1016/j.esmoop.2024.103443. Online ahead of print. ESMO Open. 2024. PMID: 38692082 Free PMC article.
Bias reduction using combined stain normalization and augmentation for AI-based classification of histological images.
Franchet C, Schwob R, Bataillon G, Syrykh C, Péricart S, Frenois FX, Penault-Llorca F, Lacroix-Triki M, Arnould L, Lemonnier J, Alliot JM, Filleron T, Brousset P. Franchet C, et al. Among authors: lacroix triki m. Comput Biol Med. 2024 Mar;171:108130. doi: 10.1016/j.compbiomed.2024.108130. Epub 2024 Feb 8. Comput Biol Med. 2024. PMID: 38387381
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, Ducoulombier A, Pistilli B, Bachelot T, Viret F, Levy C, Signolle N, Alfaro A, Tran DTN, Garberis IJ, Talbot H, Christodoulidis S, Vakalopoulou M, Droin N, Stourm A, Kobayashi M, Kakegawa T, Lacroix L, Saulnier P, Job B, Deloger M, Jimenez M, Mahier C, Baris V, Laplante P, Kannouche P, Marty V, Lacroix-Triki M, Diéras V, André F. Mosele F, et al. Among authors: lacroix triki m. Nat Med. 2023 Aug;29(8):2110-2120. doi: 10.1038/s41591-023-02478-2. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488289 Free PMC article. Clinical Trial.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Rassy E, Filleron T, Viansone A, Lacroix-Triki M, Rivera S, Desmoulins I, Serin D, Canon JL, Campone M, Gonçalves A, Levy C, Cottu P, Petit T, Eymard JC, Debled M, Bachelot T, Dalenc F, Roca L, Lemonnier J, Delaloge S, Pistilli B. Rassy E, et al. Among authors: lacroix triki m. Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29. Breast Cancer Res Treat. 2023. PMID: 36988749
Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers.
Rassy E, Garberis I, Tran-Dien A, Job B, Chung-Scott V, Bouakka I, Bassil J, Ferkh R, Lacroix-Triki M, Zanconati F, Giudici F, Generali D, Rouleau E, Lacroix L, Andre F, Pistilli B. Rassy E, et al. Among authors: lacroix triki m. Clin Cancer Res. 2023 May 1;29(9):1822-1831. doi: 10.1158/1078-0432.CCR-22-2883. Clin Cancer Res. 2023. PMID: 36805183 Free article.
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ogier du Terrail J, Leopold A, Joly C, Béguier C, Andreux M, Maussion C, Schmauch B, Tramel EW, Bendjebbar E, Zaslavskiy M, Wainrib G, Milder M, Gervasoni J, Guerin J, Durand T, Livartowski A, Moutet K, Gautier C, Djafar I, Moisson AL, Marini C, Galtier M, Balazard F, Dubois R, Moreira J, Simon A, Drubay D, Lacroix-Triki M, Franchet C, Bataillon G, Heudel PE. Ogier du Terrail J, et al. Among authors: lacroix triki m. Nat Med. 2023 Jan;29(1):135-146. doi: 10.1038/s41591-022-02155-w. Epub 2023 Jan 19. Nat Med. 2023. PMID: 36658418
102 results